References:
  1. Prestipino A, Emhardt AJ, Aumann K, O’Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Zeiser R. Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018 Feb 21;10(429)
  2. Thiele J, Kvasnicka HM, Tefferi A, Barosi G, Orazi A, Vardiman,et al. Myelofibrosis. In: Swerdlow SH, Campo E, Harris NL,Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification oftumours of haematopoietic and lymphoid tissues. Lyon:WHO; 2008. p. 44–7.
  3. Savona MR. Are we altering the natural history of primarymyelofibrosis? Leuk Res. 2014;38(9):1004–12.
  4. Ahmed RZ, Rashid M, Ahmed N, Nadeem M, Shamsi TS Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype? Asian Pac J Cancer Prey. 2016;17(3):923-6.
  5. Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW. Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. Biol Blood Marrow Transplant. 2015;21(11):1883. Epub 2015 Sep 11.
  6. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366:787.
  7. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366:799.
  8. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR; KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016 Nov 10;375(19):1823-1833. Epub 2016 Oct 8.
  9. Lee, Sze-Hwei., Lin, Chien-Chin., Wie, Chao-Hong., Chang, Ko-Ping., Yuan, Chang-Tsu., Tsai, Cheng-Hong., Liu, Jia-Hao. House, Hsin-An., Tang, Jih-Lu., Chou, Wen-Chien., Tien, Hwei-Fang. PD-L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients. The journal of Pathology: Clinical Research. September 2021.
  10. Hobbs, Gabriela. Bozkus, Cansu Cimen, Moshier, Erin, Doughterty Mikaela., Bar-Nata, Michal., Sandy, Lonette., Johnson, Kathryn., Foster, Julia Elise., Som, Tina., Macrae, Molly., Marble, Hetal., Salama, Mohamed., El Jamal, Siraj M., Zubizarreta, Nicole., Wadleigh, Martha., Stone, Richard., Bhardwaj, Nina., Iancu-Rubin, Camelia., Mascarenhas, John. PD-1 inhibiation in advanced myeloproliferative neoplasms. Blood advances. December 2021.
  11. Dall, Iman Abou Kantarjian, Jagop., Daver, Naval., Masarova, Lucia., Pemmaraju, Naveen. Bose, prithivaj., Garcia-Manero, Guillermo., Verstovsek, Srdan. Phase II study of single agente nivoulmab in patients with myelofibrosis. Ann Hematol. December 2021.